We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement
Analytical Cannabis Logo
×

Home > News > Science & Health

Coalition Calls for Sickle Cell Cannabis Clinical Trial

Published: Jul 16, 2018   

Complete the form below and we will email you a PDF version of "Coalition Calls for Sickle Cell Cannabis Clinical Trial"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Analytical Cannabis?

Analytical Cannabis Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Coalition Calls for Sickle Cell Cannabis Clinical Trial

Normal blood cells (left) and the blood cells in Sickle cell disease, which do not flow through the circulatory system smoothly. Credit: Darryl Leja, NHGRI.

In recognition of World Sickle Cell Day, a coalition led by the Sickle Cell Foundation of Georgia (SCFG), announced a fund-raising campaign to launch the first clinical trials investigating the efficacy of cannabis oil for pain associated with Sickle Cell Disease. The coalition includes Biotech, Inc. and the Phoenix Tears Foundation.


"We urge the Sickle Cell community, our friends, and allies to join in supporting the coalition as we search for alternative treatments for those battling this painful and sometimes fatal condition," said Deb McGhee McCrary, SCFG President & CEO. "These trials will fully explore the pain relief properties of medical cannabis as an alternative to highly addictive opioids."


The Georgia Legislature made history when Sickle Cell Disease was added to the list of maladies approved for Medical Cannabis opening the door for clinical trials.  This is the first clinical trial of its kind in the nation.  To assist in this effort, the public can make donations through the SCFG website www.sicklecellga.org/Donate.  


"This is important work for the thousands who suffer with SCD," added Phoenix Tears Foundation President Janet Rosendahl (Sweeney), Ph.D.  "We look forward to bringing our years of research with Cannabis to those suffering from Sickle Cell Anemia."


Babies born with sickle cell anemia can experience painful swelling of the hands and feet (Dactylitis) which requires medication and hospitalization.  In children such as Kendryln Pitts, Georgia's SCFG Poster child, joint pain, swelling and limitation of motion occur frequently.  As adults, most sickle cell patients experience pain crises requiring hospitalization, blood transfusions, and opioid painkillers. 


To date, the only cure for SCD is a bone marrow transplant, which is costly and out of reach for most patients.  According to Biotech President Dr. Jacob Savage, "Pain control represents the most practical way to ensure a better quality of life for sickle cell patients.  Medical cannabis holds great hope as a non-addictive alternative to opioids." 


Led by Biotech Research Laboratories, The Sickle Cell Medical Cannabis Clinical Trial will cost an estimated $250,000 for Phase I. 


This article has been republished from materials provided by Sickle Cell Foundation of Georgia. Note: material may have been edited for length and content. For further information, please contact the cited source.

 

Like what you just read? You can find similar content on the topic tag shown below.

Science & Health

Stay connected with the latest news in cannabis extraction, science and testing

Get the latest news with the FREE weekly Analytical Cannabis newsletter

 
Advertisement